Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5611 to 5625 of 7679 results

  1. Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when added to current practice. This includes research into optimal cut-off values for tests and the investigation of repeat testing strategies in people with intermediate levels of faecal calprotectin. Development of a consistent definition for the 'intermediate range' is encouraged.

    Recommendation ID DG11/2 Question Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when

    Research recommendation
    Published
    9 June 2015

  2. Further research is needed on the use and clinical utility of faecal calprotectin testing, and support pathways for the long-term management of these conditions in the community should be developed.

    Recommendation ID DG11/1 Question Further research is needed on the use and clinical utility of faecal calprotectin testing, and support

    Research recommendation
    Published
    9 June 2015

  3. Further research is needed to understand the effect of having the additional information provided by the adjunctive colposcopy technologies on anxiety for people having a colposcopy, when this information is shown to a person during the examination.

    Recommendation ID DG32/3 Question Further research is needed to understand the effect of having the additional information provided by

    Research recommendation
    Published
    21 November 2018

  4. Risk assessment: From the perspective of everyone involved, what works well and could be improved about the use of tools and checklists to support social work risk assessment for people with complex needs?

    Recommendation ID NG216/02 Question Risk assessment: From the perspective of everyone involved, what works well and could be improved about

    Research recommendation
    Published
    1 June 2022

  5. In infants, children and young people with overt or occult reflux, is fundoplication effective in reducing acid reflux as determined by oesophageal pH monitoring?

    Recommendation ID NG1/3 Question In infants, children and young people with overt or occult reflux, is fundoplication effective in reducing

    Research recommendation
    Published
    15 November 2019

  6. Further collection of quality of life data from people who are cured and who have experience of amputation and chemotherapy are also needed. Additional data on the health effects on parents, siblings and others with life-threatening illness would also be of value.

    Recommendation ID TA235/2 Question Further collection of quality of life data from people who are cured and who have experience of amputation

    Research recommendation
    Published
    9 June 2015

  7. Further data collection and research are recommended to assess clinical outcomes after positive and negative SeHCAT test results. This research should focus on clinical outcomes relevant to people with chronic diarrhoea, such as severity of symptoms, including urgency. Clinical outcomes should be measured in the short and long term.

    Recommendation ID DG44/02 Question Further data collection and research are recommended to assess clinical outcomes after positive and

    Research recommendation
    Published
    16 December 2021

  8. Further data collection and research are recommended to assess the effectiveness of treatment options for bile acid diarrhoea. Consideration should be given to how well the treatments are tolerated and how they affect the severity of symptoms in the longer term.

    Recommendation ID DG44/03 Question Further data collection and research are recommended to assess the effectiveness of treatment options

    Research recommendation
    Published
    16 December 2021

  9. Further data collection and research are recommended to better understand the health-related quality of life in people with bile acid diarrhoea. Consideration should be given to how quality of life differs before and after a positive or negative test and diagnosis, and how it is affected by treatment and symptom severity.

    Recommendation ID DG44/04 Question Further data collection and research are recommended to better understand the health-related quality

    Research recommendation
    Published
    16 December 2021

  10. Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium] acid) test results affect clinical decision making.

    Recommendation ID DG44/01 Question Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium]

    Research recommendation
    Published
    16 December 2021

  11. Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems on the rate at which biopsies can be done, capacity resources and waiting times for this procedure.

    Recommendation ID DG53/2 Question Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems

    Research recommendation
    Published
    11 July 2023

  12. Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the accuracy of the tests included in this assessment in the following subgroups:- people who are premenopausal- people who are postmenopausal- people with suspected early stage ovarian cancer, that is, disease apparently confined to the pelvis.Future studies should be done in populations that are representative of people with suspected ovarian cancer who are assessed in NHS secondary care.

    Recommendation ID DG31/1 Question Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the

    Research recommendation
    Published
    18 October 2018

  13. Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and its effect on healthcare resource use. myCOPD has potential for clinical benefits, but more evidence is needed to reduce uncertainties. The committee considered that comparative evidence is needed to show the clinical benefits of using myCOPD in 2 populations: people using it to self-manage COPD people referred to pulmonary rehabilitation For self-management, a randomised controlled trial is preferred to show the clinical benefits of myCOPD. This could be powered based on the encouraging results in the RESCUE study. However, a high-quality comparative observational study designed to minimise bias in the results may provide acceptable evidence. Outcomes such as rates of exacerbations, hospital readmissions and unscheduled care appointments should be considered alongside patient-reported outcomes such as health-related quality of life. For pulmonary rehabilitation, further evidence is needed to show the clinical benefits of myCOPD. This could be a randomised controlled trial which is powered based on the encouraging results in the TROOPER study or a well-designed comparative observational study. Key outcomes will be the CAT score and 6-minute walk test, ideally supported by additional longer-term outcomes such as rates of exacerbations and hospital admissions. Real-world data could be used to inform the uptake rates in the economic modelling. It should also include qualitative data on patient experience using myCOPD such as patient preferences and adherence.

    Recommendation ID MTG68/01 Question Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and

    Research recommendation
    Published
    8 April 2022

  14. A randomised controlled trial is recommended to compare DyeVert Systems  with standard care. The aim of this research would be to address uncertainties  about whether using DyeVert Systems reduces AKI incidence and rate of renal  replacement therapy after using contrast media. This must include people with  stage 4 chronic kidney disease (with an estimated glomerular filtration rate  [eGFR] under 30 ml/min/1.73 m 2 ), who are at risk of AKI and need elective  coronary or peripheral angiography.

    Recommendation ID MTG60/01 Question A randomised controlled trial is recommended to compare DyeVert Systems with standard care. The aim

    Research recommendation
    Published
    5 November 2021

  15. Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic monitoring of TNF‑alpha inhibitors in people with rheumatoid arthritis.

    Recommendation ID DG36/1 Question Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic

    Research recommendation
    Published
    25 October 2019